On May 4, 2026 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting to be held in Boston, MA, May 11–15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.

The Company will also deliver an oral presentation on FT839, its next-generation, off-the-shelf dual-CAR T cell therapy designed to simultaneously target CD19 and CD38 to eliminate pathogenic B cells, plasma cells, and activated T and NK cells, while selectively sparing non-activated immune cells. This multi-antigen targeting approach is designed to offer a unique treatment option for patients with difficult-to-treat autoimmune diseases that are multicellular in pathology, including rheumatoid arthritis and type 1 diabetes.

Additionally, the Company will present preclinical data on FT836, its next-generation, off-the-shelf CAR T-cell therapy targeting the pan-tumor stress ligands MICA/B. FT836 is shown to demonstrate potent anti-tumor activity in preclinical studies across a broad range of liquid and solid tumors without the need for conditioning chemotherapy, and can be rationally combined with standard-of-care treatments, including monoclonal antibodies, immunomodulatory drugs, and chemotherapy for enhanced clinical efficacy.

A link to the abstracts can be found here: FATE ASGCT (Free ASGCT Whitepaper)

Presentation details are as follows:

Title: FT819 Drives B cell Compartment Remodeling of Patients with Systemic Lupus Erythematosus Without Conditioning Chemotherapy

Session: Poster Reception

Poster Presentation Date / Time: Tuesday, May 12, 5:00 PM – 6:30 PM ET

Title: FT839: A multi-antigen targeting off-the-shelf dual-CAR T cell for the treatment of pathogenic B and T cells in autoimmune diseases

Session: Transforming immune modulation with gene-modified regulatory T-cells

Oral Presentation Date / Time: Thursday, May 14, 8:30 AM – 8:45 AM ET

Title: CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer

Session: Poster Reception

Poster Presentation Date / Time: Wednesday, May 13, 5:00 PM – 6:30 PM ET

(Press release, Fate Therapeutics, MAY 4, 2026, View Source [SID1234665048])